• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors May Respond To Amneal Pharmaceuticals (AMRX) Expanding Its Iohexol Generic Portfolio Across OMNIPAQUE Formats

    Simply Wall St·07/26/2026 11:21:20
    Listen to the news
    • Amneal Pharmaceuticals recently received U.S. FDA approval for additional strengths and vial sizes of its iohexol injection, a widely used radiographic contrast agent, expanding on its previously approved 300 mg iodine/mL 100 mL vials.
    • By launching the first generic versions referencing OMNIPAQUE across these presentations, Amneal aims for its broadened iohexol portfolio to cover most U.S. demand while offering providers greater flexibility and supply options in imaging procedures.
    • We’ll now examine how becoming the first generic supplier across multiple OMNIPAQUE-referenced iohexol presentations may influence Amneal’s broader investment narrative.

    The latest GPUs need a type of rare earth metal called Neodymium and there are only 29 companies in the world exploring or producing it. Find the list for free.

    Amneal Pharmaceuticals Investment Narrative Recap

    To own Amneal, you generally need to believe its mix of complex generics, injectables and biosimilars can offset ongoing U.S. pricing pressure and support profitable growth despite a leveraged balance sheet. The new iohexol approvals modestly reinforce the near term product launch pipeline and upcoming Q3 2026 launch schedule, but they do not fundamentally change the key catalyst of execution against 2026 guidance, or the major risk around margin pressure and debt loads.

    The most relevant recent announcement here is Amneal’s FDA approval of romidepsin injection in June 2026, which, along with iohexol, underscores a growing injectable and hospital portfolio. Together, these approvals highlight how new, complex sterile products could become an important supporting catalyst for earnings against consensus expectations for revenue of about US$3.05 billion to US$3.15 billion in 2026, even as broader generics pricing and regulatory scrutiny remain front of mind.

    Yet, against this opportunity, investors should also recognize the risk that higher compliance and safety expectations in areas like iohexol could...

    Read the full narrative on Amneal Pharmaceuticals (it's free!)

    Amneal Pharmaceuticals' narrative projects $3.6 billion revenue and $400.7 million earnings by 2029.

    Uncover how Amneal Pharmaceuticals' forecasts yield a $18.25 fair value, in line with its current price.

    Exploring Other Perspectives

    AMRX 1-Year Stock Price Chart
    AMRX 1-Year Stock Price Chart

    Some of the most optimistic analysts were already penciling in about US$3.8 billion of revenue and US$409.4 million of earnings by 2029, so this iohexol news may either support those ambitious biosimilar and injectable capacity assumptions or prompt you to reassess how realistic they are in light of potential underutilization risk.

    Explore 3 other fair value estimates on Amneal Pharmaceuticals - why the stock might be worth 33% less than the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Ready To Venture Into Other Investment Styles?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.